Uveitis-associated Glaucoma - Symptoms, Causes, Treatment & Prevention

```html

Overview

Uveitis‑associated glaucoma (UAG) is a secondary form of glaucoma that develops as a complication of intraocular inflammation (uveitis). The inflammation can either directly damage the trabecular meshwork—the eye’s drainage system—or lead to structural changes (e.g., peripheral anterior synechiae) that impede aqueous‑humor outflow, causing elevated intra‑ocular pressure (IOP) and optic‑nerve damage.

• Who it affects: Adults of any age can develop uveitis, but the most common etiologies (e.g., HLA‑B27‑associated anterior uveitis, sarcoidosis, Behçet’s disease) peak between 20‑40 years. When glaucoma follows, the average age of diagnosis is ~35 years, which is younger than primary open‑angle glaucoma (POAG) patients.
• Prevalence: Up to 30 % of patients with chronic or recurrent anterior uveitis will develop secondary glaucoma over a 5‑year period; population‑based studies estimate an overall incidence of 2–5 % among all uveitis patients.<sup>[1] CDC; [2] NIH</sup>
• Why it matters: Because it often occurs in younger, otherwise healthy individuals, UAG can lead to significant visual disability if not recognized early and treated aggressively.

Symptoms

Symptoms may overlap with those of uveitis itself, making it essential to monitor any change in vision or eye comfort.

• Eye pain or ache: Typically a dull, pressure‑like sensation that may worsen with eye movement.
• Redness (hyperemia): Often more pronounced around the cornea (ciliary injection) rather than diffuse conjunctival flushing.
• Blurred or hazy vision: May fluctuate with IOP spikes.
• Halos around lights: Particularly noticeable at night; a classic sign of elevated IOP.
• Decreased peripheral vision: “Tunnel vision” can develop slowly as optic‑nerve fibers are damaged.
• Photophobia: Light sensitivity commonly accompanies active uveitis but can persist if pressure remains high.
• Headache: Often described as frontal or retro‑orbital, worsening with eye strain.
• Floaters: May indicate vitreous inflammation rather than glaucoma but are worth reporting.
• Sudden loss of vision: A medical emergency suggestive of acute angle‑closure or severe IOP spike.

Causes and Risk Factors

Underlying Mechanisms

• Inflammatory obstruction of the trabecular meshwork: Cytokines, fibrin, and inflammatory cells clog the outflow channels.
• Peripheral anterior synechiae (PAS): Adhesions between the iris and cornea close the drainage angle permanently.
• Corticosteroid‑induced ocular hypertension: Topical or systemic steroids—standard uveitis therapy—raise IOP in 20‑40 % of genetically predisposed patients.<sup>[3] Mayo Clinic</sup>
• Structural remodeling: Chronic inflammation leads to extracellular‑matrix deposition and scarring that stiffen the outflow pathway.

Risk Factors

• Young to middle‑aged adults with chronic/recurrent anterior uveitis.
• Underlying autoimmune or infectious diseases (e.g., HLA‑B27 spondyloarthropathy, sarcoidosis, syphilis, tuberculosis, toxoplasmosis).
• High cumulative dose or prolonged use of topical corticosteroids.
• Family history of steroid‑responsive ocular hypertension.
• African‑American or Hispanic ancestry—higher baseline risk for glaucoma.
• History of ocular trauma or previous ocular surgery (e.g., cataract extraction).

Diagnosis

A timely diagnosis relies on both clinical assessment of the uveitis and systematic evaluation of intra‑ocular pressure and optic‑nerve health.

Clinical Examination

• Slit‑lamp biomicroscopy: Detects cells/flare in the anterior chamber, presence of PAS, and corneal edema.
• Gonioscopy: Direct visualization of the angle to assess for synechiae or angle closure.
• Tonometry: Goldmann applanation is the gold standard for IOP measurement; repeated readings help identify spikes.
• Dilated fundus exam: Evaluates optic‑nerve head for cupping, retinal nerve‑fiber‑layer (RNFL) loss, and any posterior‑segment inflammation.

Imaging & Functional Tests

• Optical Coherence Tomography (OCT): Provides high‑resolution RNFL thickness maps; progressive thinning signals glaucoma progression.
• Visual‑field testing (Humphrey or Octopus): Detects characteristic glaucomatous defects (nasal step, arcuate scotoma).
• Ultrasound biomicroscopy (UBM) or Anterior‑segment OCT: Helpful in quantifying angle closure and PAS.
• Laboratory work‑up: Tailored to suspected systemic cause (e.g., HLA‑B27 typing, ACE level, syphilis serology, TB Quantiferon).

Treatment Options

Management focuses on two parallel goals: controlling intra‑ocular inflammation and lowering IOP to a neuro‑protective level (generally <21 mm Hg, but individualized).

Anti‑Inflammatory Therapy

• Topical corticosteroids: Prednisolone acetate 1 % or difluprednate. Use the lowest effective dose and taper promptly.
• Steroid‑sparing agents:
  • Mycophenolate mofetil, azathioprine, methotrexate – for chronic disease.
  • Biologic agents (e.g., adalimumab, infliximab) – especially in HLA‑B27 or Behçet’s disease.
• Intravitreal corticosteroid implants: DEX (Ozurdex) or fluocinolone (Iluvien) can control posterior involvement but carry a higher risk of IOP rise.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): Topical ketorolac can assist in reducing flare.

IOP‑Lowering Therapy

1. Topical ocular hypotensives:
   • Prostaglandin analogues (latanoprost, bimatoprost) – most potent first‑line.
   • Beta‑blockers (timolol, betaxolol) – avoid in asthmatics or severe COPD.
   • Carbonic anhydrase inhibitors (brinzolamide, dorzolamide) – useful adjuncts.
   • Alpha‑agonists (brimonidine) – may cause allergy; use with caution.
2. Systemic medications: Oral carbonic anhydrase inhibitors (acetazolamide) for acute spikes; monitor electrolytes and renal function.
3. Laser procedures:
   • Selective Laser Trabeculoplasty (SLT) – effective in many secondary glaucomas.
   • Laser peripheral iridotomy (LPI) – only if angle‑closure component is present.
4. Surgical options (when medical therapy fails):
   • Trabeculectomy with antifibrotic agents (mitomycin‑C).
   • Glaucoma drainage devices (Ahmed, Baerveldt).
   • Minimally invasive glaucoma surgery (MIGS) – e.g., iStent, Hydrus – may be considered in mild cases with active inflammation under close follow‑up.

Lifestyle & Supportive Measures

• Limit caffeine and nicotine—they can transiently raise IOP.
• Adopt a Mediterranean‑style diet rich in omega‑3 fatty acids; evidence suggests modest IOP‑lowering effects.<sup>[4] Cleveland Clinic</sup>
• Regular moderate‑intensity exercise (e.g., walking, swimming) improves ocular blood flow.
• Protect eyes from trauma; wear protective eyewear during sports or high‑risk activities.
• Maintain a medication diary to track steroid use and IOP‑lowering drops.

Living with Uveitis‑Associated Glaucoma

Long‑term management requires a partnership between you, your ophthalmologist, and any systemic rheumatologist or infectious‑disease specialist.

Daily Management Tips

• Adherence: Use drop reminders, pillboxes, or smartphone apps to ensure consistent dosing.
• IOP monitoring: Many patients benefit from home tonometry devices (e.g., iCare) after proper training.
• Regular follow‑up: At least every 3–4 months when stable; more frequently (monthly) during active uveitis or medication changes.
• Record visual changes: Keep a simple log of any new halos, blurry spots, or peripheral vision loss.
• Contact lens wear: Soft lenses are generally safe, but discontinue during active inflammation to avoid infection.
• Travel preparation: Carry extra medication, a copy of your prescription, and a letter describing your condition for airport security.

Psychosocial Support

Living with a chronic eye disease can be stressful. Consider:

• Joining patient support groups (e.g., Glaucoma Research Foundation, Uveitis Society).
• Counseling or cognitive‑behavioral therapy for anxiety related to vision loss.
• Occupational therapy for low‑vision adaptation if visual field loss progresses.

Prevention

While you cannot always prevent uveitis, several strategies reduce the risk of subsequent glaucoma:

• Prompt treatment of uveitis: Early, adequate anti‑inflammatory therapy limits trabecular damage.
• Steroid‑sparing regimens: Discuss alternative agents with your physician, especially if you have a known steroid‑responsive IOP rise.
• Routine IOP checks: Even after the inflammation resolves, schedule periodic pressure measurements for at least 2 years.
• Control systemic disease: Good management of underlying autoimmune or infectious disorders reduces ocular flare‑ups.
• Healthy lifestyle: Balanced diet, regular exercise, and avoidance of smoking help overall ocular health.

Complications

If untreated or inadequately controlled, UAG can lead to:

• Progressive optic‑nerve damage: Irreversible visual field loss.
• Permanent cataract formation: Both inflammation and steroids accelerate lens opacification.
• Band‑keratopathy: Calcium deposition in the cornea from chronic inflammation.
• Secondary ocular hypertension after surgery: Scarring from prior procedures can complicate future interventions.
• Vision‑related quality‑of‑life decline: Difficulty with reading, driving, and independent living.
• Psychological impact: Depression and anxiety are more common in patients with chronic vision loss.

When to Seek Emergency Care

References

1. American Academy of Ophthalmology. “Uveitis and Glaucoma.” AAO Preferred Practice Pattern, 2023.
2. National Eye Institute (NEI). “Uveitis Statistics.” NIH, 2022.
3. Mayo Clinic. “Steroid‑induced Glaucoma.” Updated 2024.
4. Cleveland Clinic. “Diet and Intra‑ocular Pressure.” 2023.
5. World Health Organization. “Global Initiative for the Elimination of Avoidable Blindness.” 2021.

```